How the APOE4 gene affects brain blood flow, sleep, and waste clearance
Official title: Impaired Vasoreactivity, Sleep Degradation, and Impaired Clearance in the APOE4 Brain
Funded at University of Virginia · NIH-11453131 · Data updated 2026-11-12
This work looks at whether the APOE4 gene variant changes brain blood flow, disrupts sleep, and reduces the brain's ability to clear waste in people at higher genetic risk for Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | July 15, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $725,992 |
| NIH project number | 7R01AG072513-05 |
| Project ID | NIH-11453131 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants would be people who carry the APOE4 gene variant or are at increased genetic risk for Alzheimer's disease, often older adults or those with early cognitive symptoms.
✕Less likely to help
People who do not carry APOE4 or whose cognitive problems stem from non-AD causes may be less likely to benefit directly from findings focused on APOE4-specific mechanisms.
What this research studies
Researchers will study how the APOE4 genetic variant affects blood vessel responses, sleep stage patterns, and the brain's clearance of waste that builds up during sleep. The team will use laboratory models and advanced imaging techniques to track blood flow, vasodilation, cerebrospinal fluid movement, and markers of protein aggregation and inflammation. By linking vascular changes with sleep disruption and impaired clearance, the project aims to map a chain of events that could drive Alzheimer's pathology. Findings will focus on mechanisms tied specifically to APOE4 that might be targeted by future therapies.
Why it matters
Potential benefit: If successful, this work could point to new ways to protect brain blood flow, improve sleep, or boost waste clearance to lower Alzheimer's risk or slow disease progression for people with APOE4.
How similar studies have gone: Prior animal and human studies have linked APOE4 to vascular dysfunction, altered sleep, and reduced cerebrospinal fluid clearance, but combining these mechanisms into a causal chain is relatively new.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Proctor, Elizabeth a — University of Virginia
- Study coordinator: Proctor, Elizabeth a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.